See Local News
Get Balanced News From Your U.S. State.
See Local News
See all locals

Merck to buy Prometheus Biosciences for about $11 billion

Posted on AllSides April 16th, 2023
From The Center
REUTERS/Andrew Kelly

Merck & Co (MRK.N) has agreed to acquire Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.

The joint statement said that Merck, through one of its subsidiaries, will pay $200 per share for the biotechnology company that specializes in products for treatment of immunological diseases. That represents a 75% premium to the $114.01 closing price for Prometheus shares on Friday.

Read full story

AllSides Picks

More News about Economy and Jobs from the Left, Center and Right

From the Left

From the Center

From the Right